We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

By LabMedica International staff writers
Posted on 01 May 2024
Print article
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead to blood cancers. Interestingly, it is also present in individuals with normal blood counts, where it is linked with a heightened risk of severe atherosclerotic cardiovascular disease. Studies have shown that clonal hematopoiesis becomes more common with age, being detectable in up to 15% of individuals over 70. While it can progress to malignant blood diseases, its significant impact is the reduction in life expectancy due to an increased risk of atherosclerotic cardiovascular disease, which at its advanced stage, can cause heart attacks and strokes due to arterial blockages.

Now, a research team at the Medical University of Vienna (Vienna, Austria) has designed a genetic testing method for detecting clonal hematopoiesis. Combined with an ultrasound examination of the carotid artery, this testing approach can identify individuals at high risk for cardiovascular disease. For their research, the team focused on the impact of clonal hematopoiesis on patients with asymptomatic, verified carotid stenosis—a narrowing of the carotid artery due to atherosclerosis. They developed a novel assay employing high-throughput DNA sequencing for targeted genetic testing to detect mutations that cause clonal hematopoiesis. This testing method was applied to around 1,000 blood samples from the ICARAS study (Inflammation and Carotid Artery-Risk for Atherosclerosis Study).

The study revealed a significant increase in mortality among patients who have both carotid stenosis and clonal hematopoiesis. The joint detection of clonal hematopoiesis and carotid atherosclerosis led to the identification of a new combined biomarker that enhances the personalization of cardiovascular risk profiles. This allows for the early identification of high-risk patients, which in turn facilitates the timely adjustment of treatment plans and the prevention of the progression of atherosclerotic diseases, thereby reducing the incidence of strokes and heart attacks.

By utilizing ultrasound-based duplex sonography along with this innovative genetic testing, elevated cardiovascular risk can now be detected well before any symptoms of the disease appear. According to the researchers, “the results of this study provide the basis for future studies to investigate the role of clonal haematopoiesis in cardiovascular diseases", with the goal of implementing such genetic diagnostics in laboratory medicine.

Related Links:
Medical University of Vienna

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.